Due to the particular sensitivity of BRCA2-deficient cells to both olaparib and TRAIL, and the recent evidence on the influence of PARP-inhibition on apoptosis, we aimed at assessing the effect of combined treatment with olaparib and TRAIL in pancreatic cancer. Here, PARP1 is linked to pancreatic neoplasm.